|
EP0656947A1
(en)
|
1992-08-21 |
1995-06-14 |
Schering Corporation |
Human interleukin-13
|
|
US5635599A
(en)
|
1994-04-08 |
1997-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Fusion proteins comprising circularly permuted ligands
|
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
|
FR2742156A1
(fr)
|
1995-12-06 |
1997-06-13 |
Sanofi Sa |
Polypeptide recepteur de l'il-13
|
|
US6335426B1
(en)
*
|
1996-06-14 |
2002-01-01 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6028176A
(en)
*
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
|
US6673602B1
(en)
|
1999-06-11 |
2004-01-06 |
The General Hospital Corporation |
Herpes simplex virus amplicon vector targeting system and method of using same
|
|
US6737511B1
(en)
|
1999-08-16 |
2004-05-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
|
|
DE60038304T3
(de)
|
1999-09-09 |
2017-04-06 |
Merck Sharp & Dohme Corp. |
Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
|
|
JP2003511019A
(ja)
|
1999-10-06 |
2003-03-25 |
ザ ペン ステート リサーチ ファウンデーション |
Ｉｌ１３変異体
|
|
WO2001034645A2
(en)
|
1999-11-11 |
2001-05-17 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated il-13 molecules and their uses
|
|
GB0004016D0
(en)
|
2000-02-22 |
2000-04-12 |
Royal Brompton Hospital |
Biological material and uses thereof
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
JP4863150B2
(ja)
|
2000-08-30 |
2012-01-25 |
ザ・ペン・ステート・リサーチ・ファンデーション |
インターロイキン１３のアミノ酸置換変異体
|
|
WO2002032406A2
(en)
|
2000-10-18 |
2002-04-25 |
Massachusetts Institute Of Technology |
Methods and products related to pulmonary delivery of polysaccharides
|
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
|
IL159215A0
(en)
|
2001-06-07 |
2004-06-01 |
Wyeth Corp |
A solution of interleukin-13 and methods utilizing the same
|
|
US20040248260A1
(en)
|
2001-10-26 |
2004-12-09 |
Heavner George A. |
IL-13 mutein proteins, antibodies, compositions, methods and uses
|
|
US20060263368A1
(en)
|
2005-01-10 |
2006-11-23 |
Research Development Foundation |
Targeted chimeric molecules for cancer therapy
|
|
WO2008039173A2
(en)
|
2005-09-09 |
2008-04-03 |
Government Of The United States Of Amercica, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for inhibiting cell death or enhancing cell proliferation
|
|
WO2007048019A2
(en)
|
2005-10-20 |
2007-04-26 |
The Penn State Research Foundation |
Delivery system for diagnostic and therapeutic agents
|
|
HUE044182T2
(hu)
|
2006-06-07 |
2019-10-28 |
Genzyme Corp |
Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
|
|
WO2008101671A2
(en)
|
2007-02-19 |
2008-08-28 |
Apogenix Gmbh |
Il-4 fc fusion proteins
|
|
US9155798B2
(en)
|
2007-08-24 |
2015-10-13 |
Regents Of The University Of Minnesota |
Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
|
|
US20110077202A1
(en)
|
2008-05-16 |
2011-03-31 |
Bayer Healthcare Llc |
Targeted Coagulation Factors and Method of Using the Same
|
|
WO2010031185A1
(en)
|
2008-09-19 |
2010-03-25 |
Protox Therapeutics Inc. |
Treating cancer stem cells using targeted cargo proteins
|
|
US20100183545A1
(en)
|
2008-10-14 |
2010-07-22 |
The United States Of America, As Represented By The Secretary, |
Targeted cargo protein combination therapy
|
|
JP2010154842A
(ja)
|
2008-12-03 |
2010-07-15 |
Koji Kawakami |
Ｅｇｆｒを標的にした新規抗がんキメラペプチド
|
|
US20110023680A1
(en)
|
2009-07-30 |
2011-02-03 |
Kuo-Chung Wang |
Pcb cutter module with detachable cutters
|
|
TWI397428B
(zh)
|
2009-12-29 |
2013-06-01 |
財團法人工業技術研究院 |
標的第四介白素受體之傳輸系統
|
|
WO2011106779A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Aerovance Inc. |
Use of modified il-4 mutien receptor antagonists to treat dermatitis
|
|
US9076405B2
(en)
|
2010-03-03 |
2015-07-07 |
Sharp Kabushiki Kaisha |
Display device, method for driving same, and liquid crystal display device
|
|
US20160354472A1
(en)
|
2010-10-22 |
2016-12-08 |
Protox Therapeutics Corp. |
Use of human serum albumin to decrease antigenicity of therapeutic proteins
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
WO2012139112A1
(en)
|
2011-04-08 |
2012-10-11 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
|
|
EP2694640B1
(en)
|
2011-04-08 |
2017-10-18 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
US9512194B2
(en)
|
2012-01-27 |
2016-12-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modified IL-13 polypeptides
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
JP6936934B2
(ja)
|
2013-09-24 |
2021-09-22 |
メディシナ セラピューティクス インコーポレイテッド |
インターロイキン−４受容体結合融合タンパク質及びその使用
|
|
EP3068797B1
(en)
|
2013-11-11 |
2020-01-08 |
Wake Forest University Health Sciences |
Constructs for multi-valent targeting of tumors
|
|
ES2959480T3
(es)
|
2014-02-07 |
2024-02-26 |
Univ Mcmaster |
Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
|
|
WO2016040441A1
(en)
|
2014-09-09 |
2016-03-17 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
ES2738705T3
(es)
|
2014-09-19 |
2020-01-24 |
Hope City |
Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
|
|
EP3227317A4
(en)
|
2014-12-02 |
2018-04-25 |
Roger Williams Hospital |
Methods and compositons for treating cancer
|
|
JP6993699B2
(ja)
|
2016-01-11 |
2022-02-03 |
ウニヴェルズィテート・ツューリヒ |
ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
|
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
|
WO2019051204A1
(en)
|
2017-09-08 |
2019-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
|
|
CA3078434A1
(en)
|
2017-10-10 |
2019-04-18 |
Medicenna Therapeutics, Inc. |
Il-4-fusion formulations for treatment of central nervous system (cns) tumors
|
|
WO2020160639A1
(en)
|
2019-02-07 |
2020-08-13 |
Medicenna Therapeutics, Inc. |
Il-4r as a biomarker in cancer
|
|
EP4172216A4
(en)
|
2020-06-24 |
2024-12-04 |
Medicenna Therapeutics, Inc. |
BIFUNCTIONAL SUPERKINE AND USES THEREOF
|